Association Between MDM2 Promoter SNP309 T/G Polymorphism and Liver Cancer Risk - a Meta-analysis

Background: Many studies have investigated the association between the MDM2 promoter SNP309 T/Gpolymorphism and liver cancer risk, but inconsistencies make drawwing definitive conclusions difficult.
Methods:We therefore searched main databases for articles relating MDM2 SNP309 T/G polymorphism to risk of livercancer in humans and estimated summary odds ratio (OR) with 95% confidence intervals (95% CI) to assessthe possible association in a meta-analysis.
Results: The main analysis revealed no significant heterogeneity, andthe pooled ORs of fixed-effects were all significant (for G versus T, OR = 1.59, 95% CI 1.42-1.78; for GG versusTT, OR = 2.45, 95% CI 1.93-3.12; for GT versus TT, OR = 1.70, 95% CI 1.38-2.09; for GG versus GT, OR =1.49, 95% CI 1.24-1.79; for GG and GT versus TT, OR = 1.95, 95% CI 1.61-2.38; for GG versus TT and GT,OR = 1.73, 95% CI 1.46-2.07). Subgroup analyses by ethnicity and sensitivity analyses both showed associationsto remain significant.
Conclusion: The present meta-analysis of available data showed a significant associationbetween the MDM2 SNP309 T/G polymorphism and liver cancer risk, the MDM2 SNP309 G allele contributingto increased risk in both Asians and Caucasians in a graded, dose-dependent fashion.